Mark E Davis Selected Research

Camptothecin

1/2020	Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.
10/2019	Host immune response to anti-cancer camptothecin conjugated cyclodextrin-based polymers.
4/2016	CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing.
8/2013	First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies.
7/2013	Single-antibody, targeted nanoparticle delivery of camptothecin.
7/2009	Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements.
7/2009	Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.
5/2006	Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
3/2006	Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.
5/2004	Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark E Davis Research Topics

Disease

34	Neoplasms (Cancer) 01/2020 - 11/2003
3	Dehydration (Water Stress) 03/2016 - 04/2010
3	Heart Failure 11/2007 - 10/2005
2	Breast Neoplasms (Breast Cancer) 01/2020 - 07/2013
2	Brain Neoplasms (Brain Tumor) 01/2020 - 01/2019
2	Melanoma (Melanoma, Malignant) 02/2011 - 04/2010
2	Carcinoma (Carcinomatosis) 05/2006 - 05/2004
1	Communicable Diseases (Infectious Diseases) 01/2022
1	Infections 01/2022
1	Human Influenza (Influenza) 01/2022
1	Neoplasm Metastasis (Metastasis) 01/2019
1	Adenocarcinoma 12/2017
1	Chest Pain (Chest Pains) 12/2017
1	Stomach Neoplasms (Stomach Cancer) 12/2017
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2017
1	Esophageal Neoplasms (Esophageal Cancer) 04/2016
1	Chronic Renal Insufficiency 04/2015
1	Body Weight (Weight, Body) 08/2014
1	Squamous Cell Carcinoma of Head and Neck 05/2012
1	Drug-Related Side Effects and Adverse Reactions 10/2009
1	Lymphoma (Lymphomas) 07/2009
1	Hypersensitivity (Allergy) 04/2007
1	Heart Diseases (Heart Disease) 01/2007
1	Ewing Sarcoma (Sarcoma, Ewing) 10/2005
1	Wounds and Injuries (Trauma) 11/2004

Drug/Important Bio-Agent (IBA)

12	PolymersIBA 01/2022 - 05/2004
11	Small Interfering RNA (siRNA)IBA 12/2015 - 10/2005
10	CamptothecinIBA 01/2020 - 05/2004
9	CyclodextrinsIBA 01/2022 - 11/2003
9	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2020 - 05/2004
9	IT-101IBA 10/2019 - 03/2006
7	Transferrin (beta 2 Transferrin)IBA 01/2010 - 11/2003
6	Pharmaceutical PreparationsIBA 01/2020 - 03/2006
5	Irinotecan (Camptosar)FDA LinkGeneric 12/2017 - 05/2004
5	LigandsIBA 01/2010 - 11/2003
4	Cytidine Diphosphate (CDP)IBA 01/2022 - 05/2004
4	Transferrin Receptors (Transferrin Receptor)IBA 05/2009 - 11/2003
3	Nucleic AcidsIBA 01/2022 - 11/2003
3	Biological ProductsIBA 04/2016 - 11/2003
3	AcidsIBA 03/2016 - 04/2010
3	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 02/2011 - 04/2007
3	UrocortinsIBA 11/2007 - 10/2005
2	Trastuzumab (Herceptin)FDA Link 01/2020 - 07/2013
2	galactaric acid (mucic acid)IBA 01/2020 - 07/2013
2	5-hydroxymethylfurfural (hydroxymethylfurfural)IBA 03/2016 - 04/2010
2	ethyleneIBA 03/2016 - 06/2014
2	Lewis AcidsIBA 03/2016 - 06/2014
2	Silicon Dioxide (Silica)FDA LinkGeneric 03/2016 - 06/2014
2	AntibodiesIBA 05/2015 - 04/2007
2	CALAA-01IBA 08/2014 - 05/2009
2	EnzymesIBA 02/2011 - 07/2004
2	cyclodextrin polymerIBA 07/2009 - 11/2003
2	DNA (Deoxyribonucleic Acid)IBA 07/2009 - 07/2004
1	Pathogen-Associated Molecular Pattern MoleculesIBA 01/2022
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2022
1	Epidermal Growth Factor (EGF)IBA 01/2020
1	CollagenIBA 01/2017
1	Carbonic Anhydrase IXIBA 04/2016
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 04/2016
1	Tumor Biomarkers (Tumor Markers)IBA 04/2016
1	ZincIBA 03/2016
1	furanIBA 03/2016
1	SolventsIBA 03/2016
1	HydrocarbonsIBA 03/2016
1	EstersIBA 03/2016
1	dimethyl 4-phthalate (dimethyl terephthalate)IBA 03/2016
1	Panitumumab (Vectibix)FDA Link 05/2015
1	Cetuximab (Erbitux)FDA Link 05/2015
1	TinIBA 06/2014
1	ZeolitesIBA 06/2014
1	hexamethylene bisacetamide (HMBA)IBA 06/2014
1	AT 61IBA 06/2014
1	Therapeutic UsesIBA 04/2011
1	Temozolomide (Temodar)FDA LinkGeneric 02/2011
1	FructoseIBA 04/2010
1	Starch (Cornstarch)IBA 04/2010
1	Glucose (Dextrose)FDA LinkGeneric 04/2010
1	GoldIBA 01/2010
1	AntidotesIBA 10/2009
1	trioctyl phosphine oxide (TOPO)IBA 07/2009
1	polycationsIBA 03/2008
1	Proteins (Proteins, Gene)FDA Link 03/2008
1	LuciferasesIBA 09/2007
1	pro-brain natriuretic peptide (1-76)IBA 02/2006
1	Natriuretic PeptidesIBA 02/2006
1	Atrial Natriuretic Factor (ANF)IBA 02/2006
1	Metoprolol (Toprol-XL)FDA LinkGeneric 02/2006
1	Brain Natriuretic Peptide (Natrecor)FDA Link 02/2006
1	EWS-FLI fusion proteinIBA 10/2005
1	Hormones (Hormone)IBA 10/2005
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2004
1	RNA (Ribonucleic Acid)IBA 07/2004
1	Catalytic DNA (Deoxyribozyme)IBA 07/2004
1	Single-Stranded DNA (DNA, Single Stranded)IBA 07/2004

Therapy/Procedure

17	Therapeutics 01/2020 - 11/2003
4	Drug Therapy (Chemotherapy) 12/2017 - 01/2008
2	Intravenous Injections 05/2012 - 03/2008
2	Injections 01/2010 - 07/2004
2	Intravenous Administration 03/2008 - 05/2006
1	Aftercare (After-Treatment) 04/2010